Share on StockTwits

PDL BioPharma (NASDAQ:PDLI) saw a significant growth in short interest in May. As of May 30th, there was short interest totalling 31,649,801 shares, a growth of 9.7% from the May 15th total of 28,862,804 shares, StockRatingsNetwork reports. Currently, 21.3% of the company’s stock are sold short. Based on an average daily trading volume, of 1,980,237 shares, the short-interest ratio is presently 16.0 days.

Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of PDL BioPharma in a research note on Wednesday, May 14th. They now have a $9.00 price target on the stock.

PDL BioPharma (NASDAQ:PDLI) opened at 9.71 on Friday. PDL BioPharma has a one year low of $7.38 and a one year high of $10.21. The stock’s 50-day moving average is $8.93 and its 200-day moving average is $8.63. The company has a market cap of $1.559 billion and a price-to-earnings ratio of 5.56.

PDL BioPharma (NASDAQ:PDLI) last posted its quarterly earnings results on Monday, May 12th. The company reported $0.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by $0.01. The company had revenue of $139.70 million for the quarter, compared to the consensus estimate of $130.93 million. During the same quarter in the previous year, the company posted $0.36 earnings per share. The company’s revenue for the quarter was up 52.2% on a year-over-year basis. On average, analysts predict that PDL BioPharma will post $2.06 earnings per share for the current fiscal year.

PDL BioPharma, Inc (NASDAQ:PDLI) is a is a biotech company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.